Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

12 févr. 2014 08h55 HE | Source: Mateon Therapeutics

OXiGENE, Inc. Announces $12 Million Public Offering

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) today announced that it has entered into definitive agreements with investors to purchase an aggregate of...
30 janv. 2014 06h00 HE | Source: Mateon Therapeutics

OXiGENE Announces Presentation at BIO CEO Conference on February 11th

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
27 nov. 2013 16h00 HE | Source: Mateon Therapeutics

OXiGENE Appoints Frederick W. Driscoll to Its Board of Directors

SOUTH SAN FRANCISCO, Calif., Nov. 27, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the...
18 nov. 2013 16h00 HE | Source: Mateon Therapeutics

OXiGENE Announces Preclinical Data Presentation on Novel Anticancer Compounds, Benzosuberenes, Demonstrating Potent Anti-Proliferative Activity

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
18 nov. 2013 09h00 HE | Source: Mateon Therapeutics

OXiGENE to Present Phase I Data Demonstrating Antitumor Activity of OXi4503 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
12 nov. 2013 16h00 HE | Source: Mateon Therapeutics

OXiGENE Reports Third Quarter 2013 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial...
04 nov. 2013 16h30 HE | Source: Mateon Therapeutics

OXiGENE Announces Third Quarter 2013 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., Nov. 4, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report third...
04 nov. 2013 16h30 HE | Source: Mateon Therapeutics

OXiGENE to Present at BIO-Europe Conference on November 6th

SOUTH SAN FRANCISCO, Calif., Nov. 4, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
21 oct. 2013 09h00 HE | Source: Mateon Therapeutics

OXiGENE Presents Preclinical Data Demonstrating Significant Antitumor Activity of ZYBRESTAT(R) in Pancreatic Neuroendocrine Tumor Model

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the...
15 oct. 2013 16h00 HE | Source: Mateon Therapeutics

OXiGENE to Present Preclinical Data Demonstrating Antitumor Activity of ZYBRESTAT(R) in Pancreatic Neuroendocrine Tumor Model

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...

Page précédente